Abstract
A series of aminoalkanol and amino acid derivatives of trans-cinnamic acid as well as aminoalkanol derivatives of α-phenylcinnamic acid was synthesized and evaluated for anticonvulsant activity. All compounds were verified in mice after intraperitoneal (i.p.) administration in maximal electroshock (MES) and subcutaneous pentetrazole (ScMet) induced seizures as well as neurotoxicity assessment. Six of them showed protection in MES at 100 mg/kg b.w. and one at 300 mg/kg b.w. For selected derivatives evaluation in ScMet test in rats after per os (p.o.) administration, 6-Hz test in mice and pilocarpine-induced status in rats were performed. The results are quite encouraging and further modification of the structures might lead to discovering new potential anticonvulsants.
Keywords: Amino acid derivatives, Aminoalkanol derivatives, Anticonvulsant, MES, ScMet, Synthesis, Cinnamic acid derivatives, trans-cinnamic, aminoalkanol, intaperitoneal, pilocarpine, subcutaneous pentetrazole (ScMet), trans-a-phenylcinnamic, Oxytropis pseudoglandulosa, toluene/K2CO3, acylation, polarimeter
Letters in Drug Design & Discovery
Title: Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives
Volume: 9 Issue: 1
Author(s): Agnieszka Gunia, Anna M. Waszkielewicz, Marek Cegla and Henryk Marona
Affiliation:
Keywords: Amino acid derivatives, Aminoalkanol derivatives, Anticonvulsant, MES, ScMet, Synthesis, Cinnamic acid derivatives, trans-cinnamic, aminoalkanol, intaperitoneal, pilocarpine, subcutaneous pentetrazole (ScMet), trans-a-phenylcinnamic, Oxytropis pseudoglandulosa, toluene/K2CO3, acylation, polarimeter
Abstract: A series of aminoalkanol and amino acid derivatives of trans-cinnamic acid as well as aminoalkanol derivatives of α-phenylcinnamic acid was synthesized and evaluated for anticonvulsant activity. All compounds were verified in mice after intraperitoneal (i.p.) administration in maximal electroshock (MES) and subcutaneous pentetrazole (ScMet) induced seizures as well as neurotoxicity assessment. Six of them showed protection in MES at 100 mg/kg b.w. and one at 300 mg/kg b.w. For selected derivatives evaluation in ScMet test in rats after per os (p.o.) administration, 6-Hz test in mice and pilocarpine-induced status in rats were performed. The results are quite encouraging and further modification of the structures might lead to discovering new potential anticonvulsants.
Export Options
About this article
Cite this article as:
Gunia Agnieszka, M. Waszkielewicz Anna, Cegla Marek and Marona Henryk, Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192982
DOI https://dx.doi.org/10.2174/157018012798192982 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Cardiovascular effect of Nigella sativa L. Aqueous Extract in Normal Rats
Cardiovascular & Hematological Disorders-Drug Targets Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Types of Voltage-Gated Calcium Channels: Molecular and Electrophysiological Views
Current Hypertension Reviews Nanoemulgel: A Promising Phase in Drug Delivery
Current Pharmaceutical Design Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Characterisation and Modulation of Neuroplasticity in Humans
Current Neuropharmacology Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry Anticonvulsant Activity of New GABA Prodrugs
Medicinal Chemistry Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design The Beneficial Effect of Rice Bran Extract Against Rotenone-Induced Experimental Parkinson’s Disease in Rats
Current Molecular Pharmacology Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase.
CNS & Neurological Disorders - Drug Targets L-Type Calcium Channels
Current Pharmaceutical Design Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
CNS & Neurological Disorders - Drug Targets Topiramate Decelerates Bicarbonate-Driven Acid-Elimination of Human Neocortical Neurons: Strategic Significance for its Antiepileptic, Antimigraine and Neuroprotective Properties
CNS & Neurological Disorders - Drug Targets